HER2 status: A statistician's view

Annals of Oncology

Volumn 12, Issue SUPPL. 1, 2001, Pages

  Valagussa, P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

HER2; Predictive factor; Prognostic factor; Statistical significance

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; TAMOXIFEN;

ACCURACY; ADVANCED CANCER; ARTICLE; BIOSTATISTICS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG SENSITIVITY; HUMAN; METASTASIS; ONCOGENE NEU; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

EID: 0034877246     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/12.suppl_1.S29     Document Type: Article

References (28)

1. EGF-related peptides and their receptors in mammary gland development
2. EGF-related peptides in the pathophysiology of the mammary gland
3. Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer
4. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
5. Studies of HER-2/neu protooncogene in human breast and ovarian cancer
6. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
7. The role of immunohistochemistry and fluorescence in situ hybridization for HER-2/neu in assessing the prognosis of breast cancer
8. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
9. State of the art in comparative cancer clinical trials
10. Statistical problems in the reporting of clinical trials. A survey of three medical journals
11. Reporting results from chemotherapy trials. Does response make a difference in patient survival?
12. Guidelines for publishing papers on cancer clinical trials: Responsibilities of editors and authors
13. Current issues in the design and interpretation of clinical trials
14. Patient subsets and variation in therapeutic efficacy
15. Covariate adjustment of treatment effects in clinical trials
16. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
17. Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up
18. Elevated serum c-erb B-2 antigen levels and decreased response to hormonal therapy of breast cancer
19. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
20. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
21. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study
22. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary node metastases
23. Prognostic importance of c-erbB-2 expression in breast cancer
24. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
25. Response to CMF in lymph node positive breast cancer according to HER2 overexpression and other tumor biologic variables
26. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
27. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer